A Phase I/II Dose Escalation Trial of Udenafil in Adolescents With Single Ventricle Physiology After Fontan Palliation

Trial Profile

A Phase I/II Dose Escalation Trial of Udenafil in Adolescents With Single Ventricle Physiology After Fontan Palliation

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Apr 2015

At a glance

  • Drugs Udenafil (Primary)
  • Indications Congenital heart defects; Ventricular dysfunction
  • Focus Adverse reactions
  • Sponsors Mezzion
  • Most Recent Events

    • 26 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 16 Mar 2015 A preliminary review of results was positive, according to a Mezzion Pharma media release.
    • 04 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top